Literature DB >> 24112502

Recurrent urolithiasis following parathyroidectomy for primary hyperparathyroidism.

C Rowlands1, A Zyada, S Zouwail, H Joshi, M J Stechman, D M Scott-Coombes.   

Abstract

INTRODUCTION: The effect of parathyroidectomy on the incidence of recurrent stone formation is uncertain. We aimed to compare the biochemistry and recurrence rate of urolithiasis in patients with primary hyperparathyroidism (pHPT) and stone formation (SF) and non-stone formation (NSF) with idiopathic stone formers (ISF).
METHODS: Patients with pHPT and SF (Group 1) were identified from a prospective database. pHPT patients and NSF (Group 2) and ISFs (Group 3) were randomly selected from respective databases to form three equal groups. Preoperative and postoperative biochemical data were analysed and recurrent urolithiasis diagnosed if present on follow-up radiology. Out-of-area patients were asked about recurrence via telephone.
RESULTS: From July 2002 to October 2011, 640 patients had parathyroidectomy for pHPT. Of these, 66 (10.3%) had a history of renal colic; one was lost to follow-up. Patient demographics were similar across all three groups. Three months post-parathyroidectomy, Groups 1 and 2 had significantly reduced serum calcium concentrations (p<0.01). Group 1 had lower urinary calcium excretion after parathyroidectomy (p<0.01), but estimated glomerular filtration rate did not change following surgery. During median follow-up of 4.33 years (0.25-9 years) in Groups 1 and 2 and 5.08 years (0.810-8 years) in Group 3, one patient (1.5%) in Group 1 and 16 patients (25%) in Group 3 had recurrent urolithiasis (p<0.01). No Group 2 patients developed stones.
CONCLUSION: Curative parathyroidectomy confers a low recurrence rate for urolithiasis, but does not prevent recurrence in all patients. Further research should aim to identify the risk factors for continued SF in these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24112502      PMCID: PMC5827286          DOI: 10.1308/003588413X13629960048712

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  28 in total

Review 1.  Epidemiology of stone disease.

Authors:  Gary C Curhan
Journal:  Urol Clin North Am       Date:  2007-08       Impact factor: 2.241

2.  Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor gene regulatory region.

Authors:  Giuseppe Vezzoli; Annalisa Terranegra; Teresa Arcidiacono; Giovanni Gambaro; Luciano Milanesi; Ettore Mosca; Laura Soldati
Journal:  Nephrol Dial Transplant       Date:  2010-01-12       Impact factor: 5.992

3.  Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor.

Authors:  Somchai Chutipongtanate; Yasushi Nakagawa; Suchai Sritippayawan; Jeeraporn Pittayamateekul; Paisal Parichatikanond; Bruce R Westley; Felicity E B May; Prida Malasit; Visith Thongboonkerd
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

4.  Patients with primary hyperparathyroidism--why do some form stones?

Authors:  Aaron D Berger; Wilfred Wu; Brian H Eisner; Matthew R Cooperberg; Quan-Yang Duh; Marshall L Stoller
Journal:  J Urol       Date:  2009-03-17       Impact factor: 7.450

5.  Renal stone epidemiology: a 25-year study in Rochester, Minnesota.

Authors:  C M Johnson; D M Wilson; W M O'Fallon; R S Malek; L T Kurland
Journal:  Kidney Int       Date:  1979-11       Impact factor: 10.612

6.  The effect of parathyroidectomy on the recurrence of nephrolithiasis.

Authors:  T F Deaconson; S D Wilson; J Lemann
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

7.  Gain-of-function haplotype in the epithelial calcium channel TRPV6 is a risk factor for renal calcium stone formation.

Authors:  Yoshiro Suzuki; Andreas Pasch; Olivier Bonny; Markus G Mohaupt; Matthias A Hediger; Felix J Frey
Journal:  Hum Mol Genet       Date:  2008-02-13       Impact factor: 6.150

8.  Primary hyperparathyroidism: renal calcium excretion in patients with and without renal stone sisease before and after parathyroidectomy.

Authors:  Vibe G Frøkjaer; Charlotte L Mollerup
Journal:  World J Surg       Date:  2002-02-19       Impact factor: 3.352

9.  Is parathyroidectomy of benefit in primary hyperparathyroidism?

Authors:  S Posen; P Clifton-Bligh; T S Reeve; C Wagstaffe; M Wilkinson
Journal:  Q J Med       Date:  1985-03

10.  Primary hyperparathyroidism: is there an increased prevalence of renal stone disease?

Authors:  Jane M Suh; John J Cronan; Jack M Monchik
Journal:  AJR Am J Roentgenol       Date:  2008-09       Impact factor: 3.959

View more
  4 in total

1.  Analysis of Primary Hyperparathyroidism Screening Among US Veterans With Kidney Stones.

Authors:  Calyani Ganesan; Benjamin Weia; I-Chun Thomas; Shen Song; Kyla Velaer; Carolyn D Seib; Simon Conti; Chris Elliott; Glenn M Chertow; Manjula Kurella Tamura; John T Leppert; Alan C Pao
Journal:  JAMA Surg       Date:  2020-09-01       Impact factor: 16.681

Review 2.  Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.

Authors:  A A Khan; D A Hanley; R Rizzoli; J Bollerslev; J E M Young; L Rejnmark; R Thakker; P D'Amour; T Paul; S Van Uum; M Zakaria Shrayyef; D Goltzman; S Kaiser; N E Cusano; R Bouillon; L Mosekilde; A W Kung; S D Rao; S K Bhadada; B L Clarke; J Liu; Q Duh; E Michael Lewiecki; F Bandeira; R Eastell; C Marcocci; S J Silverberg; R Udelsman; K Shawn Davison; J T Potts; M L Brandi; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-09-09       Impact factor: 4.507

3.  "Silent" kidney stones in "asymptomatic" primary hyperparathyroidism-a comparison of multidetector computed tomography and ultrasound.

Authors:  Andreas Selberherr; Marcus Hörmann; Gerhard Prager; Philipp Riss; Christian Scheuba; Bruno Niederle
Journal:  Langenbecks Arch Surg       Date:  2016-10-12       Impact factor: 3.445

Review 4.  Primary Hyperparathyroidism.

Authors:  Leonardo Bandeira; John Bilezikian
Journal:  F1000Res       Date:  2016-01-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.